Hearn Cho, MD, Hematology, New York, NY, Mount Sinai Hospital

HearnJayChoMD

Hematology New York, NY

Assistant Professor, Medicine, Icahn School of Medicine at Mount Sinai

Dr. Cho is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Cho's full profile

Already have an account?

Education & Training

  • New York Presbyterian Hospital
    New York Presbyterian HospitalFELLOWSHIP
  • University of California San Diego
    University of California San DiegoRESIDENCY
  • Weill Cornell Medical College of Cornell University
    Weill Cornell Medical College of Cornell UniversityMEDICAL_SCHOOL

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2000 - 2021
  • CA State Medical License
    CA State Medical License 1998 - Present
  • American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • A Machine Learning Approach Identifies a 30-Gene Model That Predicts Sensitivity to Selinexor in Multiple Myeloma
    Hearn Jay Cho, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • ADAR1 Drives Disease Progression in Multiple Myeloma By Acting Both As an RNA Editor of Specific Transcripts and As a DNA Mutator of Their Cognate Genes
    Hearn Jay Cho, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Outcomes in Multiple Myeloma Patients Progressing on Lenalidomide Maintenance
    Hearn Jay Cho, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

  • High Dimensional Immune Profiling in Smoldering Multiple Myeloma Identifies Novel Organizing Features of the Tumor Microenvironment 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Mechanisms of CD4 T Cell Tumor Immunity in a Preclinical Model of Multiple Myeloma 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Increased HLA-E Expression Correlates with Early Relapse in Multiple Myeloma 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • MMRF CureCloud® Aims to Accelerate Precision Medicine with Real-World Data in Myeloma
    MMRF CureCloud® Aims to Accelerate Precision Medicine with Real-World Data in MyelomaJuly 21, 2020
  • COVID-19 & Multiple Myeloma: Delay ASCT
    COVID-19 & Multiple Myeloma: Delay ASCTMarch 27, 2020
  • MMRF Research Programs Drives New Breakthroughs in Multiple Myeloma Research
    MMRF Research Programs Drives New Breakthroughs in Multiple Myeloma ResearchSeptember 13, 2019
  • Join now to see all

Grant Support

  • Type 1 MAGE Vaccine Immunotherapy For Multiple MyelomaNational Cancer Institute2006–2010

Professional Memberships

Hospital Affiliations